Arsenic Trioxide Has Additive Cytotoxic Effects on MCF-7 Breast Cancer Cell Line With Taxanes

Canfeza SEZGİN

Makale detayları

Arsenic Trioxide Has Additive Cytotoxic Effects on MCF-7 Breast Cancer Cell Line With Taxanes

Yazarlar:

Canfeza SEZGİN

Yayıncı:

TUBITAK

Dergi:

Turkish Journal of Medical Sciences 2002 Vol.32 Issue 6, pp.439-444

Belge Tipi:

Makale

Yayın Tarihi:

5/2002

Belge Dili:

Türkçe

Document ID (Org No.):

2000756857

Sıklık:

İki Aylık

eISSN:

1303-6165

pISSN:

1300-0144

Anahtar kelimeler:

Özet:

 

Breast cancer is the most prevalent cancer in women and an important cause of both morbidity and mortality. Although long-term disease-free survival is offered to women with early stage disease by current treatment modality, some, 30-40% of patients will have metastatic disease. Treatment of patients with metastatic disease is a great challenge for oncologists. Therefore, new drugs and therapeutic options for women with metastatic breast cancer are urgently required.    Arsenical compounds have cytotoxic effects on several cancer cell lines including promyelocytic leukemia, esophageal carcinoma, megakaryocytic leukemia, and malignant lymphocytic cell lines. In addition, recent studies showed that arsenic trioxide (As2O3) can induce a clinical remission in patients with acute promyelocytic leukemia.  In this study, we evaluated the cytotoxic effects of arsenic trioxide (As2O3) alone and combined with Taxane compounds (paclitaxel and docetaxel) on human breast carcinoma cell line MCF-7. It is clearly demonstrated that As2O3 has a significant cytotoxic effect on breast carcinoma cells. IC50 for As2O3 was 5 x 10-6 M after 72 h. Apoptosis of carcinoma cells was responsible for the cytotoxicity of As2O3. The additive effects of taxane compounds with As2O3 were shown. These in vitro results may suggest that As2O3 is a potential new cytotoxic agent for the treatment of breast cancer.

 

Breast cancer is the most prevalent cancer in women and an important cause of both morbidity and mortality. Although long-term disease-free survival is offered to women with early stage disease by current treatment modality, some, 30-40% of patients will have metastatic disease. Treatment of patients with metastatic disease is a great challenge for oncologists. Therefore, new drugs and therapeutic options for women with metastatic breast cancer are urgently required.    Arsenical compounds have cytotoxic effects on several cancer cell lines including promyelocytic leukemia, esophageal carcinoma, megakaryocytic leukemia, and malignant lymphocytic cell lines. In addition, recent studies showed that arsenic trioxide (As2O3) can induce a clinical remission in patients with acute promyelocytic leukemia.  In this study, we evaluated the cytotoxic effects of arsenic trioxide (As2O3) alone and combined with Taxane compounds (paclitaxel and docetaxel) on human breast carcinoma cell line MCF-7. It is clearly demonstrated that As2O3 has a significant cytotoxic effect on breast carcinoma cells. IC50 for As2O3 was 5 x 10-6 M after 72 h. Apoptosis of carcinoma cells was responsible for the cytotoxicity of As2O3. The additive effects of taxane compounds with As2O3 were shown. These in vitro results may suggest that As2O3 is a potential new cytotoxic agent for the treatment of breast cancer.

Makale detayları

Arsenic Trioxide Has Additive Cytotoxic Effects on MCF-7 Breast Cancer Cell Line With Taxanes

Yazarlar: Canfeza SEZGİN

Yayıncı: TUBITAK

Dergi: Turkish Journal of Medical Sciences 2002 Vol.32 Issue 6, pp.439-444

Belge Tipi: Makale

Yayın Tarihi: 5/2002

Belge Dili: Türkçe

Document ID (Org No.): 2000756857

Sıklık: İki Aylık

eISSN: 1303-6165

pISSN: 1300-0144

breast cancer

MCF-7

arsenic trioxide

docetaxel

paclitaxel

Sayı

Yazarlar:

Canfeza SEZGİN

Yayıncı:

TUBITAK

Dergi:

Turkish Journal of Medical Sciences 2002 Vol.32 Issue 6, pp.439-444

Belge Tipi:

Makale

Yayın Tarihi:

5/2002

Belge Dili:

Türkçe

Document ID (Org No.):

2000756857

Sıklık:

İki Aylık

eISSN:

1303-6165

pISSN:

1300-0144